Table 1

Clinical characteristics of the study population

All patients
(p value)
Age (years)81.2±5.382±5.480.7±5.30.244
Female, n (%)52 (52)16 (46)36 (55)0.170
Weight (kg)70.9±13.472.1±13.170.2±13.50.505
Height (cm)161.1±7.7162.7±8160.1±7.40.110
BSA (m2)1.78±0.191.8±0.191.76±0.180.329
BMI (kg/m2)27.3±4.727.2±4.427.4±4.90.854
TAPSE pre-TAVR (mm)22±2.622.4±2.621.7±2.50.285
AVA baseline (cm2)0.75±0.150.74±0.120.76±0.170.498
AV mean gradient pre-TAVR (mm Hg)47.9±13.447.8±12.848.1±13.90.920
AV peak gradient pre-TAVR (mm Hg)74.4±18.574.7±18.574.3±18.60.912
LVEF pre-TAVR (%)53.7±9.154.0±9.253.6±9.10.848
LVEDD pre-TAVR (mm)50.2±6.249.9±650.4±6.30.746
LVESD pre-TAVR (mm)33.8±7.233.2±5.734.1±80.610
IVSd pre-TAVR (mm)12.9±1.612.9±1.712.9±1.60.996
LAVi pre-TAVR (mL/m2)48.1±13.848.5±14.147.9±13.80.865
Aortic regurgitation pre-TAVR, n (%)0.066
 None18 (18)5 (14)13 (20)
 Mild48 (48)20 (57)28 (43)
 Mild-to-moderate34 (34)10 (29)24 (37)
PASP (mm Hg)39±11.138.5±10.439.3±11.60.793
average E/E‘13.5±3.312.9±2.613.9±3.50.234
EuroSCORE II (%)6.8±4.77.1±4.66.6±4.80.644
Creatinine (mg/dL)1.2±0.91.1±0.51.3±10.317
GFR (mL/min)54.9±21.758.1±24.153±20.10.279
AV mean gradient post-TAVR (mm Hg)9.7±4.88.6±3.810.4±5.30.088
LAVi post-TAVR (mL/m2)47.3±15.350.4±17.443.8±12.20.281
LVEF post-TAVR (%)53.4±8.853.5±8.253.4±9.30.983
Average E/E‘ post-TAVR12.2±2.612.4±2.712±2.50.731
Aortic regurgitation post-TAVR, n (%)0.962
 None37 (37)12 (34)25 (38)
 Mild57 (57)21 (60)36 (55)
 Mild-to-moderate6 (6)2 (6)4 (6)
  • AV, aortic valve; AVA, aortic valve area; BMI, body mass index; BSA, body surface area; E/A, early-to-late diastolic flow ratio; E/E’, E-to-mean E’ ratio; GFR, glomerular filtration rate; IVSd, interventricular septal diameter diastolic; LAVi, left atrial volume index; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane excursion; TAVR, transcatheter aortic valve replacement.